切换至 "中华医学电子期刊资源库"

中华实验和临床感染病杂志(电子版) ›› 2023, Vol. 17 ›› Issue (01) : 1 -5. doi: 10.3877/cma.j.issn.1674-1358.2023.01.001

综述

系统性红斑狼疮合并活动性结核病研究进展
马亚楠1, 侍效春2, 刘晓清3,()   
  1. 1. 100730 北京,中国医学科学院北京协和医学院,北京协和医院,疑难重症及罕见病国家重点实验室,感染内科
    2. 100730 北京,中国医学科学院北京协和医学院,北京协和医院,疑难重症及罕见病国家重点实验室,感染内科;100730 北京,中国医学科学院北京协和医学院,结核病研究中心
    3. 100730 北京,中国医学科学院北京协和医学院,北京协和医院,疑难重症及罕见病国家重点实验室,感染内科;100730 北京,中国医学科学院北京协和医学院,结核病研究中心;100730 北京,中国医学科学院北京协和医学院,国际临床流行病学网,临床流行病学教研室
  • 收稿日期:2022-07-27 出版日期:2023-02-15
  • 通信作者: 刘晓清
  • 基金资助:
    "十二五"国家科技重大专项(No. 2014ZX10003003); "十三五"国家科技重大专项(No. 2017ZX10201302-003); 中国医学科学院医学与健康科技创新工程项目(No. 2016-I2M-1-013、2019-I2M-2-005)

Research progress on systemic lupus erythematosus compicated with active tuberculosis

Yanan Ma1, Xiaochun Shi2, Xiaoqing Liu3,()   

  1. 1. Division of Infectious Diseases, Department of Internal Medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
    2. Division of Infectious Diseases, Department of Internal Medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China; Center for Tuberculosis Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
    3. Division of Infectious Diseases, Department of Internal Medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China; Center for Tuberculosis Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China; Clinical Epidemiology Unit, Peking Union Medical College, International Clinical Epidemiology Network, Beijing 100730, China
  • Received:2022-07-27 Published:2023-02-15
  • Corresponding author: Xiaoqing Liu
引用本文:

马亚楠, 侍效春, 刘晓清. 系统性红斑狼疮合并活动性结核病研究进展[J/OL]. 中华实验和临床感染病杂志(电子版), 2023, 17(01): 1-5.

Yanan Ma, Xiaochun Shi, Xiaoqing Liu. Research progress on systemic lupus erythematosus compicated with active tuberculosis[J/OL]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2023, 17(01): 1-5.

系统性红斑狼疮(SLE)是一种多器官多系统受累的慢性自身免疫性疾病。感染是导致SLE患者发病和死亡最常见的原因之一。与普通人群相比,SLE患者感染事件发生风险显著增加。其中,活动性结核病(ATB)作为单一传染性疾病的重要死因,与SLE间的相互作用较为复杂。一方面SLE患者因本身免疫功能异常及激素和免疫抑制剂的使用,更易发生结核病;另一方面,结核分枝杆菌感染诱发的免疫激活又是SLE发生发展的危险因素之一,两者互为因果。当SLE患者并发ATB时,临床症状往往不典型,很难与SLE本身活动或其他感染相鉴别,易造成漏诊及误诊;且病情重,发生播散性肺结核及肺外结核比例显著升高。本文就SLE患者发生ATB的临床特点进行综述,为更好地认知SLE合并ATB提供一定依据。

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease, characterized by a multitude of autoantibodies and multiorgan damage. Infections are the most common causes of the morbidity and mortality of patients with SLE. The risk of infection in SLE patients is significantly higher than the general population. Active tuberculosis (ATB), as a single infectious etiology of death, has a complex relationship with SLE. On the one hand, patients with SLE always increased the susceptibility to tuberculosis due to autoimmune disorder and the use of glucocorticoids and immunosuppressants. On the other hand, immune activation induced by tuberculosis infection can predispose patients to the occurrence and development of SLE; the two causes interact as both cause and effect. When patients with SLE are complicated with ATB, the clinical symptoms are often atypical, and it is difficult to distinguish it from SLE itself or other infections, which is easy to cause missed diagnosis and misdiagnosis, and the disease is serious, and the proportion of disseminated tuberculosis and extrapulmonary tuberculosis increased significantly. This paper reviews the clinical characteristics of ATB of patients with SLE, which provides some basis for better cognition of SLE complicated with ATB in clinical practice.

表1 系统性红斑狼疮合并结核病的主要研究
表2 系统性红斑狼疮预防性抗结核治疗的主要研究
[1]
World Health Organization. Global tuberculosis report 2021[EB/OL]. World Health Organization2021.

URL    
[2]
Oku K, Hamijoyo L, Kasitanon N, et al. Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements[J]. Int J Rheum Dis,2021,24(7):880-895.
[3]
Pego-Reigosa JM, Nicholson L, Pooley N, et al. The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis[J]. Rheumatology (Oxford),2021,60(1):60-72.
[4]
Barber MRW, Clarke AE. Systemic lupus erythematosus and risk of infection[J]. Expert Rev Clin Immunol,2020,16(5):527-538.
[5]
穆克利. 系统性红斑狼疮患者感染结核分枝杆菌后血清免疫指标变化及临床意义 [J/CD]. 中华实验和临床感染病杂志(电子版),2014,8(5):627-630.
[6]
Doaty S, Agrawal H, Bauer E, et al. Infection and lupus: which causes which?[J]. Curr Rheumatol Rep,2016,18(3):13.
[7]
González-Naranjo LA, Coral-Enríquez JA, Restrepo-Escobar M, et al. Factors associated with active tuberculosis in Colombian patients with systemic lupus erythematosus: a case-control study[J]. Clin Rheumatol,2021,40(1):181-191.
[8]
Askanase AD, Yazdany J, Molta CT. Post-marketing experiences with belimumab in the treatment of SLE patients[J]. Rheum Dis Clin North Am,2014,40(3):507-17, viii.
[9]
Felten R, Dervovic E, Chasset F, et al. The 2018 pipeline of targeted therapies under clinical development for Systemic Lupus Erythematosus: a systematic review of trials[J]. Autoimmun Rev,2018,17(8):781-790.
[10]
全国第五次结核病流行病学抽样调查技术指导组, 全国第五次结核病流行病学抽样调查办公室. 2010年全国第五次结核病流行病学抽样调查报告[J]. 中国防痨杂志,2012,34(8):485-508.
[11]
Liu X, Zhang L, Zhang F, et al. Prevalence and risk factors of active tuberculosis in patients with rheumatic diseases: a multi-center, cross-sectional study in China[J]. Emerg Microbes Infect,2021,10(1):2303-2312.
[12]
Xiao X, Da G, Xie X, et al. Tuberculosis in patients with systemic lupus erythematosus-a 37-year longitudinal survey-based study[J]. J Intern Med,2021,290(1):101-115.
[13]
Lao M, Chen D, Wu X, et al. Active tuberculosis in patients with systemic lupus erythematosus from Southern China: a retrospective study[J]. Clin Rheumatol,2019,38(2):535-543.
[14]
Muhammed H, Jain A, Pattanaik SS, et al. Clinical spectrum of active tuberculosis in patients with systemic lupus erythematosus[J]. Rheumatol Int,2021,41(12):2185-2193.
[15]
Hamijoyo L, Candrianita S, Rahmadi A R, et al. The clinical characteristics of systemic lupus erythematosus patients in Indonesia: a cohort registry from an Indonesia-based tertiary referral hospital[J]. Lupus,2019,28(13):1604-1609.
[16]
Cheng CF, Huang YM, Lu CH, et al. Prednisolone dose during treatment of tuberculosis might be a risk factor for mortality in patients with systemic lupus erythematosus: a hospital-based cohort study[J]. Lupus,2019,28(14):1699-1704.
[17]
Greenstein L, Makan K, Tikly M. Burden of comorbidities in South Africans with systemic lupus erythematosus[J]. Clin Rheumatol,2019,38(8):2077-2082.
[18]
Yang Y, Thumboo J, Tan BH, et al. The risk of tuberculosis in SLE patients from an Asian tertiary hospital[J]. Rheumatol Int,2017,37(6):1027-1033.
[19]
中华人民共和国国家卫生和计划生育委员会. 肺结核诊断标准(WS 288-2017)[J/CD]. 新发传染病电子杂志,2018,3(1):59-61.
[20]
Sargin G, Senturk T, Ceylan E, et al. TST, QuantiFERON-TB Gold test and T-SPOT. TB test for detecting latent tuberculosis infection in patients with rheumatic disease prior to anti-TNF therapy[J]. Tuberk Toraks,2018,66(2):136-143.
[21]
边赛男, 刘晓清. γ-干扰素释放试验在免疫功能抑制人群中诊断结核分枝杆菌感染的应用[J/CD]. 中华实验和临床感染病杂志(电子版)2017,11(2):117-120.
[22]
Zhang L, Zhang Y, Shi X, et al. Utility of T-cell interferon-gamma release assays for diagnosing tuberculous serositis: a prospective study in Beijing, China[J]. PLoS One,2014,9(1):e85030.
[23]
Palavutitotai N, Buppajarntham T, Katchamart W. Etiologies and outcomes of pleural effusions in patients with systemic lupus erythematosus[J]. J Clin Rheumatol,2014,20(8):418-421.
[24]
Chen DY, Huang YH, Chen YM, et al. ANA positivity and complement level in pleural fluid are potential diagnostic markers in discriminating lupus pleuritis from pleural effusion of other aetiologies[J]. Lupus Sci Med,2021,8(1):e000562.
[25]
Silva JE, Silva C, Pacheco M, et al. Simultaneous systemic lupus erythematosus flare and disseminated tuberculosis: Balancing anti-mycobacterial and autoimmune treatments[J]. Cureus,2021,13(10):e18944.
[26]
World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management[M]. Geneva, 2018.
[27]
国家卫生健康委员会办公厅. 国家卫生健康委办公厅关于印发中国结核病预防控制工作技术规范(2020年版)的通知[EB/OL]. (2020-04-02) [2020-06-10].

URL    
[28]
中国防痨协会. 高危人群结核分枝杆菌潜伏感染检测及预防性治疗专家共识[J]. 中国防痨杂志,2021,43(9):874-878.
[29]
Gaitonde S, Pathan E, Sule A, et al. Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long term steroid treatment [J]. Ann Rheum Dis,2002,61(3):251-253.
[30]
马丽, 林冰, 王丽英, 等. 预防治疗系统性红斑狼疮患者医源性活动性结核病的临床观察 [J]. 中华医学杂志,2014,45(4):3579-3582.
[31]
Mok MY, Lo Y, Chan TM, et al. Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy[J]. J Rheumatol,2005,32(4): 609-615.
[32]
谢其冰, 尹耕. 应用异烟肼预防系统性红斑狼疮患者结核感染的作用评估[J]. 四川大学学报(医学版),2008,39(3):519-520.
[33]
赵利军, 刘桂枝. 异烟肼预防系统性红斑狼疮患者结核感染的临床分析[J]. 世界最新医学信息文摘,2015,15(98):74-75.
[1] 农云洁, 黄小桂, 黄裕兰, 农恒荣. 超声在多重肺部感染诊断中的临床应用价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(09): 872-876.
[2] 李小飞, 刘洪莉, 石丘玲, 田静, 李莉, 漆洪波, 罗欣. 自然分娩产妇低强度聚焦超声子宫复旧治疗防治产后出血的前瞻性随机对照研究[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(05): 534-539.
[3] 许月芳, 刘旺, 曾妙甜, 郭宇姝. 多粘菌素B和多粘菌素E治疗外科多重耐药菌感染临床疗效及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 700-703.
[4] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[5] 皮尔地瓦斯·麦麦提玉素甫, 李慧灵, 艾克拜尔·艾力, 李赞林, 王志, 克力木·阿不都热依木. 生物补片修补巨大复发性腹壁切口疝临床疗效分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 624-628.
[6] 顾熙, 徐子宇, 周澍, 张吴楼, 张业鹏, 林昊, 刘宗航, 嵇振岭, 郑立锋. 腹股沟疝腹膜前间隙无张力修补术后补片感染10 例报道[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 665-669.
[7] 臧宇, 姚胜, 朱新勇, 戎世捧, 田智超. 低温等离子射频消融治疗腹壁疝术后补片感染的临床效果[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 687-692.
[8] 杨闯, 马雪. 腹壁疝术后感染的危险因素分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 693-696.
[9] 邢嘉翌, 龚佳晟, 祝佳佳, 陆群. 肺癌化疗患者继发肺部感染的病原菌耐药性及炎症因子变化分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 714-718.
[10] 王石林, 叶继章, 丘向艳, 陈桂青, 邹晓敏. 慢性阻塞性肺疾病真菌感染风险早期预测分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 773-776.
[11] 董大红, 周明虎, 李芝朋, 许正峰. 碳青霉烯类抗生素联合呼吸机治疗肺部感染的临床疗效分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 793-796.
[12] 中华医学会器官移植学分会. 肝移植术后缺血性胆道病变诊断与治疗中国实践指南[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 739-748.
[13] 丛黎, 马林, 陈旭, 李文文, 张亮亮, 周华亭. 改良CT严重指数联合炎症指标在重症急性胰腺炎患者胰腺感染预测及预后评估中的研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 432-436.
[14] 贾玲玲, 滕飞, 常键, 黄福, 刘剑萍. 心肺康复在各种疾病中应用的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 859-862.
[15] 颜世锐, 熊辉. 感染性心内膜炎合并急性肾损伤患者的危险因素探索及死亡风险预测[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 618-624.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?